Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | UNG | P13051 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045298 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TP53UNGMEN1KMT2A | |
| SCHEMBL4383489 | 0.84 | HPGD (0.56) | EPHX2ALDH1A1TP53UNGMEN1 | |
| Ammonia Solution, Strong SCHEMBL28325064 | 0.83 | ERN1 (0.55) | EPHX2ALDH1A1TP53UNGMEN1 | |
| SCHEMBL522002 | 0.82 | CHRNA7 (0.61) | EPHX2CHRNA7HRH3ALDH1A1MEN1 | |
| SCHEMBL15650472 | 0.82 | HPGD (0.61) | ALDH1A1TP53UNGMEN1KMT2A | |
| SCHEMBL15156204 | 0.82 | MEN1 (0.47) | ALDH1A1TP53UNGMEN1KMT2A | |
| SCHEMBL10195744 | 0.81 | HPGD (0.68) | EPHX2CHRNA7ALDH1A1TP53HTT | |
| SCHEMBL1471436 | 0.81 | HPGD (0.62) | ALDH1A1TP53UNGMEN1KMT2A | |
| SCHEMBL13503747 | 0.80 | SMN1; SMN2 (0.70) | EPHX2ALDH1A1GAAHTT | |
| SCHEMBL13503921 | 0.80 | MEN1 (0.68) | CHRNA7HRH3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558595-B1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-25 | — | — | EP | disclosed |
| EP-1558595-B1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-25 | — | — | EP | disclosed |
| CN-100558718-C | Piperazinyl and diazacyclo heptyl benzene methane amide and thiobenzamide | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-11 | — | — | CN | disclosed |
| US-7414047-B2 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7414047-B2 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7414047-B2 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | disclosed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | disclosed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | disclosed |
| CN-1729180-A | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | CN | disclosed |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | HRH2, HNMT, HRH3 | EPHX2 1050/4885CHRNA7 297/4885HRH3 3/4885 |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | HRH2, HNMT, HRH3 | EPHX2 1050/4885CHRNA7 297/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.